MPN

Society Pass (Nasdaq: SOPA)/Thoughtful Media Group Acquires More Media, Indonesia-based Digital Design and Branding Agency

Retrieved on: 
Wednesday, December 28, 2022
Well, Ecosystem, TMG, Social media, F&B, Advertising, The Co Founder, SOPA, USD, Sopa, Acquisition, Business development, MPN, Entrepreneurship, Logistics, Internet, Internet celebrity, US, Social commerce, Sales, Online shopping, Beauty, Media, SEA

Jakarta, Indonesia, Dec. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Thoughtful Media Group Inc (“Thoughtful Media” or “TMG”), the Thailand-based social commerce-focused, premium digital advertising network of Society Pass Incorporated ("SoPa”) (Nasdaq: SOPA), Southeast Asia’s (SEA) next generation, data-driven, loyalty, fintech and e-commerce ecosystem, today announces the acquisition of More Media, a leading Indonesia-based creative design and branding agency. The More Media acquisition extends TMG’s social commerce and influencer advertising business reach beyond Thailand and Vietnam and into the booming Indonesia digital advertising sector.

Key Points: 
  • The More Media acquisition extends TMG’s social commerce and influencer advertising business reach beyond Thailand and Vietnam and into the booming Indonesia digital advertising sector.
  • With its focus on storytelling and providing end-to-end branding services, More Media has onboarded a diverse roster of clients such as Langsre, Emilia, Kei Dining, and Allino.
  • Post acquisition, More Media is re-branded as Thoughtful Media Indonesia with its Co-Founder, Eugenia Agnes Gusti, appointed as VP of Business Development for Thoughtful Media to drive sales and onboard Indonesia clients onto the regional TMG digital advertising platform.
  • More Media seamlessly blends into our product and geographical growth strategy for TMG as we enter yet another leading SEA market.

Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC)

Retrieved on: 
Thursday, January 5, 2023
Clinical trial, US FDA, ODD, Food, MYC, Squamous cell carcinoma, Therapy, Phenotype, Acute myeloid leukemia, Person, Disease, Leukemia, Patient, RCOR1, Degenerative disease, Therapeutic index, MPN, Diamond–Blackfan anemia, FDA, AML, Wilms' tumor, US, Jubilant, Thrombocythemia, Pharmaceutical industry, Mobile phone, SCLC

BEDMINSTER, N.J., Jan. 5, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc ., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation for JBI-802 for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML).

Key Points: 
  • BEDMINSTER, N.J., Jan. 5, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc ., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation for JBI-802 for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML).
  • This unique profile has shown synergistic anti-tumor activity and it is expected to overcome tolerability limitations of first-generation, single target epigenetic modulators.
  • "JBI-802 is the lead product candidate from our TIBEO (Therapeutic Index and Brain Exposure Optimization) Discovery Engine.
  • It is our unique approach of structure-based drug design to generate novel pharmacophores with improved target product profile compared to existing agents.

CURE Media Group announces winners of the 2022 MPN Heroes Recognition Program

Retrieved on: 
Friday, December 9, 2022
H. Lee Moffitt Cancer Center & Research Institute, Survivor, Pancreatic serous cystadenoma, Diagnosis, Leukemia, Motivation, Human, Therapy, PV, Lymphatic system, Polycythemia vera, Science, Cancer, Memorial Sloan Kettering Cancer Center, Radio, Knowledge, MPN, Education, Organization, Weill Cornell Medicine, Research, Social media, Caregiver, Patient, MD Anderson Cancer Center, Medical device, Medicine, Pharmaceutical industry, Incyte

CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced the recipients of the 2022 MPN Heroes® Recognition Program.

Key Points: 
  • CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced the recipients of the 2022 MPN Heroes® Recognition Program.
  • “This year marks the tenth anniversary of the MPN Heroes® Recognition Program, and we are honored to recognize these individuals who have made a difference in MPN care.”
    The recipients of the 2022 MPN Heroes® Recognition Program are:
    Mayra D. Andújar Delgado, who is a fierce advocate for patients in the MPN community.
  • For more information on the 2022 MPN Heroes® Recognition Program, click here.
  • Incyte Corporation partners with CURE Media Group to support the program, with CURE® hosting the annual MPN Heroes recognition ceremony.

AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Titan IIIB, BAT, AOP, Union, Royal commission, MPN, Patient, EMA, Research, Critical care, Phlebotomy, PV, Hydroxycarbamide, Drug development, Health, European Commission, Multimedia, Safety, ELN, ATC, ASH, Polycythemia, Renewable energy, Pharmaceutical industry, Bookkeeping, Ropeginterferon alfa-2b

AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Healths CONTINUATION-PV study ( Reference Kiladjian et al.

Key Points: 
  • AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Healths CONTINUATION-PV study ( Reference Kiladjian et al.
  • ASH 2022 ) and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health ( Reference Barbui et al.
  • ASH 2022 ) presented at ASH 2022 Annual Meeting, New Orleans, USA.
  • With this development program AOP Health obtained the first marketing authorization ever of BESREMi for the treatment of Polycythaemia Vera by the European Commission (2019), followed by Switzerland, Liechtenstein and Israel.

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Therapy, Pancreatic serous cystadenoma, Spleen, MD, Poster, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, MSK, Ajax, Myeloproliferative neoplasm, Memorial Sloan Kettering Cancer Center, Type, Type 2, Disease, Reticulocyte, JAK2, Bone marrow, Senior, Computational chemistry, Hematocrit, Secondary research, ASH, Pharmaceutical industry, Primary myelofibrosis, Leukemia

In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.

Key Points: 
  • In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.
  • Were very encouraged by the first preclinical data on our Type II JAK2 inhibitor program being presented today at the ASH Annual Meeting, said Craig E. Masse, PhD, Senior Vice President, Discovery Research at Ajax Therapeutics.
  • This data supports our findings that Type II JAK2 inhibitors can significantly reduce the mutant allele burden that drives MPNs which is not observed with Type I JAK2 inhibitors, such as ruxolitinib.
  • Ajax Therapeutics , Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.

Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Therapy, Pancreatic serous cystadenoma, Srđan, MD, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, Section, International Work Group for Indigenous Affairs, MD Anderson Cancer Center, MSK, Ajax, Memorial Sloan Kettering Cancer Center, Myeloproliferative neoplasm, Division, Executive Committee, School of Dental Medicine, University of Zagreb, Committee, JAK2, American Society for Clinical Investigation, University, Computational chemistry, SAB, Pharmaceutical industry, Primary myelofibrosis, Leukemia

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).
  • I am pleased to be joining the Ajax SAB at this exciting stage of the companys development, said Dr. Verstovsek.
  • Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.
  • NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics.

Trialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 Percent

Retrieved on: 
Monday, December 5, 2022
Pancreatic serous cystadenoma, Invention, MPN, Patient, COVID-19 pandemic in the Democratic Republic of the Congo, Cancer, Oncology, TIME, Drug development, AI, Cros, Lymphatic system, Clinical trial, Database, Pharmaceutical industry

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Trialjectory ("the Company"), an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials, announced today it is currently working with more than 50 pharmaceutical companies, emerging biotechs and Contract Research Organizations to develop and execute clinical trials that focus more on patients' unique medical and personal needs – an increase of 800 percent since the beginning of 2020.

Key Points: 
  • With more than 3 million treatment matches to date, Trialjectory has grown its database from 2,000 clinical trials in 2019 to over 20,000 trials in 2022.
  • "The first step toward increasing all enrollment in clinical studies is to address the fears and myths about what it means to participate in a clinical trial.
  • "Since partnering with Trialjectory, MPNRF has accelerated clinical trial access for patients living with myeloproliferative neoplasms (MPN).
  • Working directly with patients, healthcare providers and pharmaceutical companies, Trialjectory democratizes access to advanced cancer treatment and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials.

CURE Media Group announces Vanessa Bayer as keynote speaker for the 2022 MPN Heroes® Recognition Program 

Retrieved on: 
Friday, December 2, 2022
Therapy, The National WWII Museum, Bayer, Pancreatic serous cystadenoma, Survivor, MPN, Leukemia, Season, Patient, The National, CURE, Cancer, Dream, University, Friends, Motivation, Research, Caregiver, Education, Organization, Pharmaceutical industry, Incyte

CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced Emmy-nominated actress, writer and comedian Vanessa Bayer as the keynote speaker of the 2022 MPN Heroes Recognition Program.

Key Points: 
  • CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced Emmy-nominated actress, writer and comedian Vanessa Bayer as the keynote speaker of the 2022 MPN Heroes Recognition Program.
  • We are truly delighted that Vanessa Bayer will join us to deliver the keynote address at this years MPN Heroes recognition ceremony, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of CURE Media Group.
  • The recipients of the 2022 MPN Heroes Recognition Program, who have made a significant impact in the MPN blood cancer community, will be announced at the event.
  • Incyte Corporation partners with CURE Media Group to support the program, with CURE hosting the annual MPN Heroes recognition ceremony.

Kaizen Clean Energy Becomes Extreme E’s Official Clean Energy Technology Provider

Retrieved on: 
Wednesday, November 30, 2022
EV, Electric Vehicles, Sports, Off-Road Trucks & SUVs, Motor Sports, Sustainability, Alternative Energy, Energy, Automotive, Environment, Other Manufacturing, Automotive Manufacturing, Manufacturing, Hydrogen, Niobium, Midnight, IOT, Financial Times, Transport, Eden Reforestation Projects, EV, Energy & Water Ombudsman, Motor vehicle, Agriculture, City, Enel, Entrepreneurship, Risk, General Applied Science Laboratory, CBMM, Electronics, Zenith, PIMCO, Wind, Insurance, Trust, Mobility, Allianz, EY, MEC, Sport, Life, Red, Environment, Ernst & Young Entrepreneur of the Year Award, Research, Extreme E, Water, New Future Coalition Party, Vodafone, Dream, Safety, Allianz Global Investors, El Primero, Chassis, MPN, English, Woman, Tree, Continental, Management, Renewable energy, Recycling, Online shopping, Risk management, NEOM

ENOWA benefits from NEOM's greenfield site, which has no legacy infrastructure, to advance Energy, Water, and Hydrogen innovation.

Key Points: 
  • ENOWA benefits from NEOM's greenfield site, which has no legacy infrastructure, to advance Energy, Water, and Hydrogen innovation.
  • ENOWA will act as a catalyst and incubator for developing new, sustainable energy and water businesses while creating a robust economic sector regionally.
  • Founded in 1871, the technology company offers safe, efficient, intelligent, and affordable solutions for vehicles, machines, traffic and transportation.
  • CBMM | Niobium is a founding supplier of Extreme E and the Championships official Niobium Technology Supplier and Chassis Technology Supplier.

Pharmaessentia to Host Investor Day in New York City on November 30, 2022

Retrieved on: 
Monday, November 21, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, 101 Park Avenue, Hematology, Biotechnology, Learning Technology Partners, Interferon alfa-2b, MD Anderson Cancer Center, Polycythemia, Pancreatic serous cystadenoma, Q&A, PEC, MPN, Hospital, Park Avenue, Dana–Farber Cancer Institute, PV, Fine chemical, Brigham

PharmaEssentia USA Corporation (PEC USA) , a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m.

Key Points: 
  • PharmaEssentia USA Corporation (PEC USA) , a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m.
  • ET, at Convene (101 Park Avenue) in New York City.
  • The event will include a detailed discussion on the impact of BESREMi (ropeginterferon alfa-2b-njft) in polycythemia vera (PV), its market opportunity and the Company's future-focused scientific strategy.
  • A live webcast and replay of the event will be available on the PharmaEssentia USA website at https://us.pharmaessentia.com/ .